Invasive Haemophilus influenzae and Haemophilus influenzae serotype b (Hib) have been described as important causes of disease and death in children, immunocompromised persons, and adults with certain underlying medical conditions [1] [2] [3] [4] [5] [6] . Hib was once the most common cause of bacterial meningitis in children aged #5 years in the United States [5, 6] . After the introduction of Hib polysaccharide vaccine in 1985 and Hib conjugate vaccines during 1987-1990, the incidence of invasive H. influenzae disease among children aged ,5 years decreased by .99% [5, [7] [8] [9] . However, rates of invasive H. influenzae and Hib remain higher among American Indian and Alaska Native children [10, 11] .
With the dramatic reduction of Hib disease in young children because of universal vaccination, the epidemiological trends of H. influenzae have shifted, and recent reports describe an increase of disease in adults aged .65 years [12] and an increase of H. influenzae disease caused by non-b encapsulated serotypes [13] [14] [15] .
Surveillance for H. influenzae disease is essential to monitor for shifts in disease incidence, to understand the burden of invasive H. influenzae disease, and to develop public health prevention strategies. The greatest burden of disease occurs at both ends of the life spectrum-in the youngest infants and in older adults. We analyzed data from 20 years of active, population-and laboratory-based surveillance for invasive H. influenzae infection in a large, multistate catchment area to describe the epidemiology and characterize trends in the incidence of H. influenzae infection in the United States.
METHODS

Surveillance
Active, population-and laboratory-based surveillance for invasive H. influenzae disease was conducted from 1 January 1989 through 31 December 2008 as part of Active Bacterial Core surveillance (ABCs). ABCs is supported by the United States Centers for Disease Control and Prevention (CDC) as part of its Emerging Infections Program Network, as described elsewhere [16] .
The surveillance areas included California ( A case of invasive H. influenzae was defined as isolation of H. influenzae from a normally sterile site (eg, blood or cerebrospinal fluid [CSF]) in a surveillance area resident. Epidemiologic and clinical information was abstracted from medical records. Outcome of illness was based on patient status at the time of hospital discharge; no information was collected on whether the death was attributed to H. influenzae infection. Regular laboratory audits were conducted to identify cases missed during routine surveillance.
The following hierarchical definition was used to assign a single syndrome for cases: a patient was defined as having meningitis if a clinical diagnosis of meningitis had been reported in the patient's medical record or if H. influenzae was isolated from a CSF sample and as having pneumonia if pneumonia was reported in the patient's medical record and H. influenzae was isolated from a blood or pleural fluid sample. A patient was defined as having septic arthritis if H. influenzae was isolated from a joint fluid sample and as having isolated bacteremia if H. influenzae was isolated from a blood sample and no localized clinical syndrome was described.
Laboratory Methods
Serotyping of H. influenzae was done at state public health laboratories, after which the isolates were sent to the CDC, where serotype was confirmed by slide agglutination. The CDC result was used as the final serotype. If an isolate was nonviable or contaminated on arrival at CDC after sending 2 times, the result from the state laboratory was used. In this analysis, H. influenzae isolates were classified on the basis of their serotype; serotype b (Hib), nontypeable (nonencapsulated), and non-b (serotypes a, c, d, e, and f).
Statistical Analyses
Incidence rates were calculated using US Census data for the ABCs sites, and estimates of the number of cases and deaths in the 50 states were calculated standardizing for race and age group. Rates calculated for 1989 used 1990 population estimates as denominators, because appropriate race stratifications were not available in 1989 census data. For rate calculations, an ABCs site was included only if data were collected for the complete year. The 95% confidence interval (CI) around the standardized rate was calculated using a method derived from the relationship between Poisson distribution and the gamma distribution [17] . Incidence rates are reported as cases per 100 000 population. Trends over time were assessed using the Cochran-Armitage test for trend; when data were not linear, we reported the percentage change in incidence.
Race was classified as white, black, American Indian and Alaska Native, or Asian/Pacific Islander. Patients with unknown race were distributed based on the known racial distribution in each ABCs site and age group. The case-fatality ratio was calculated using the proportion of cases with known outcomes as the denominator.
RESULTS
Current Epidemiology: 1999-2008
During 1999-2008, 4838 cases of H. influenzae disease were reported from ABCs sites, resulting in an estimated mean annual incidence of 1.62 cases per 100 000 population; 15.3% of cases were fatal. An estimated 4725 cases of H. influenzae disease occurred annually in the United States during this period, with an estimated 3625 cases in 1999 and 4700 cases in 2008. The mean annual incidence of H. influenzae disease ranged from 1.26 to 2.00 cases per 100,000 population (median, 1.59 cases per 100,000 population) among surveillance sites. Table 1 shows the standardized incidence and case-fatality ratio associated with H. influenzae disease by age group and serotype during 1999-2008. Incidence was highest among children aged ,1 year and adults aged $65 years. Table 2 shows the epidemiologic characteristics of patients with nontypeable and non-b H. influenzae disease by age group.
H. influenzae was isolated from blood in 4414 cases (91.2%), CSF in 259 cases (5.4%), joint fluid in 54 cases (1.1%), pleural fluid in 84 cases (1.7%), and peritoneal fluid in 71 cases (1.5%). In 72 cases (1.5%), H. influenzae was isolated from both blood and CSF samples. Information on syndrome was available for 4584 cases (94.7%). Pneumonia was the most frequent clinical syndrome (53.3%), followed by bacteremia (34.7%) and meningitis (7.6%). The median age of patients with pneumonia was 70 years (range, 0-110 years), whereas the median age of patients with bacteremia was 52 years (range, 0-105 years) and with meningitis was 29.5 years (range, 0-96 years). The majority of patients were hospitalized (90.7%); the median duration of hospitalization was 6 days (range, 0-609 days). Patients with bacteremia were hospitalized a median of 6 days (range, 0-609 days), patients with pneumonia were hospitalized a median of 7 days (range, 0-309 days), and patients with meningitis were hospitalized a median of 9 days (range, 0-98 days). Isolates 6%) were ,34 weeks, and 104 (72.2%) were ,37 weeks (range, 23-43 weeks). Birth weight was available for 150 infants; 68 (45.3%) were ,1500 g, and 94 (62.7%) were ,2500 g (range, 482-4189 g). One hundred sixty-one (92%) of cases in infants aged ,1 month occurred during the first week of life (,7 days), and 95% of disease was caused by nontypeable organisms.
Epidemiology in Children Aged
The burden of H. influenzae disease among American Indian and Alaska Native children is much greater than that in the general US population. Incidence by race and serotype among children aged ,5 years is shown in Table 3 . Serotypes a and b are more frequent causes of invasive disease in American Indian and Alaska Native children, compared with non-Native children, whereas nontypeable cases are more common in non-Native children, compared with American Indian and Alaska Native children (Table 3) .
With the successful use of Hib vaccine in children aged ,5 years, the incidence of Hib disease has decreased to 0.23 cases per 100,000 population. Nontypeable H. influenzae has become an important cause of invasive disease among children aged ,5 years, with an estimated incidence of 1.73 cases per 100,000 population; 62.5% of cases in this age group were caused by nontypeable H. influenzae. Among infants aged ,1 year, 66.9% of cases were caused by nontypeable H. influenzae. Compared with children with Hib disease, children with nontypeable H. influenzae are significantly more likely to present with bacteremia than with meningitis (data not shown).
Epidemiology in Adults Aged $65 Years
The incidence of invasive H. influenzae is higher among adults aged $65 years than among other age groups ( Table 1 ). The risk of disease continues to increase with increasing age; among adults aged 65-69 years, incidence was 3.55 cases per 100 000 population; among persons aged 70-74 years, incidence was 4.62 cases per 100 000 population; among persons aged 75-79 years, incidence was 5.92 cases per 100 000 population; among persons aged 80-85 years, incidence was 7.81 cases per 100 000 population; and among persons aged $85 years, incidence was 13.48 cases per 100 000 population. The proportion of disease that occurs in black persons aged $65 years is substantially lower than that in other age groups (Table 2) . A higher proportion of patients aged $65 years were hospitalized (data not shown), and patients in this age group had a higher case-fatality ratio (Table 1) . Among persons aged $65 years, 19.5% were residents of nursing homes; 22.8% and 7.3% of patients infected with nontypeable and non-b H. influenzae, respectively, were nursing home residents. Among persons aged $85 years, 38.1% were residents of nursing homes; 40.2% and 18.1% of patients infected with nontypeable and non-b H. influenzae, respectively, were nursing home residents. In the United States, 4% of the population aged $65 years and 14% of the population aged $85 years are residents of nursing homes [18] .
Trends in Disease Incidence: 1989-2008
During 1989-2008, 7559 cases of H. influenzae disease were reported from ABCs sites. During 1989-1998, 76% of isolates were available for serotyping, and during 1999-2008, 87% of isolates were available for serotyping. In 1989, 79.7% of invasive disease was caused by Hib and 16.8% by nontypeable strains. By 2008, only 3.0% of invasive disease was caused by Hib and 68.4% by nontypeable strains. The estimated mean annual incidence of H. influenzae infection decreased by 65%, from 4.39 cases per 100 000 population in 1989 to 1.55 cases per 100 000 population in 2008. H. influenzae infection incidence among children aged ,5 years decreased from 37.18 cases per 100 000 population in 1989 to 3.09 cases per 100 000 population in 2008 (92% decrease) (Figure 1 ), mostly because of decreases in the incidence of Hib infection. Among adults $65 years, H. influenzae infection incidence remained largely stable (12% decrease); however, large increases in the incidence of infection caused by non-b types and nontypeable strains were observed. Figure 2 shows trends in the incidence of invasive H. influenzae disease caused by non-b encapsulated serotypes; the largest increase in incidence was observed for serotype f (0.06 cases per 100 000 population in 1989 to 0.25 cases per 100 000 population in 2008; 317% increase). Serotype f was observed primarily among adults, with 83% of cases reported in adults aged $18 years.
During the study period, the median age of patients increased significantly. In 1989, the median patient age for patients with non-b and nontypeable cases was 28 years (range, 0-96 years), and 31.9% of patients were aged ,5 years, whereas in 2008, the median patient age had increased to 63 years (range, 0-100 years), and 48.2% of patients were $65 years of age.
DISCUSSION
The epidemiology of invasive H. influenzae infection has shifted dramatically in the post-Hib vaccination era, with the majority of the disease now caused by nontypeable H. influenzae in all age groups. Overall decreases in H. influenzae infection incidence among children aged ,5 years have persisted, but rates of H. influenzae disease among adults aged $65 years have remained largely stable. The largest burden of H. influenzae disease continues to occur in the youngest and oldest age groups. Many cases in children aged ,5 years occur during the first month of life, in preterm or low-birth weight infants. An estimated 10% of the total burden of disease among children aged ,5 years occurs in American Indian and Alaska Native children, who account for 1% of the total population of children aged ,5 years in the United States. Historically, American Indian and Alaska Native children have been at increased risk of Hib disease. This may be attributable to continued transmission in adverse living conditions (eg, household crowding, poverty, and poor indoor air quality) disproportionally experienced by many American Indian and Alaska Native children [11] . Invasive H. influenzae disease is associated with severe outcomes, and among persons aged $65 years, nearly 25% of cases result in death. Risk factors for disease and whether clinical outcomes in older persons are directly to the result of invasive H. influenzae disease or of complications of other underlying medical conditions remain unclear.
The epidemiology of H. influenzae at the national level is similar to reports from local areas [12, 15] and other countries post-Hib implementation [19, 20] . However, it is difficult to assess whether observed increases in rates of H. influenzae disease are true increases in disease or a result of improved surveillance over the past 20 years. ABCs methods have not changed significantly, but there have likely been improvements in clinical practice, laboratory testing, and recognition of H. influenzae disease over time, particularly in the older age groups.
The non-Hib invasive disease burden might be an opportunity for prevention through development of new vaccines. The epidemiology of invasive disease suggests these vaccines should not target capsular antigens, because most disease is caused by nontypeable H. influenzae and a high level of genetic diversity has been found among nontypeable H. influenzae isolates [21, 22] . A pneumococcal vaccine licensed in Europe is conjugated to protein D, a protein found on the outer membrane of H. influenzae organisms, which may have broad coverage against H. influenzae [23] . Protein-based vaccines are being developed for broad coverage against pneumococcal organisms, which could serve as a model for future H. influenzae vaccines. Moreover, H. influenzae vaccines with broad coverage may have a substantial impact on noninvasive disease, such as otitis media, pneumonia, and sinusitis [24] .
Understanding how H. influenzae is being transmitted, especially to neonates and older persons, may help to determine for which age groups vaccination should be targeted for the greatest disease prevention. To be most effective, H. influenzae vaccines should have an impact on nasopharyngeal carriage, because the populations at greatest risk are the most difficult to protect through primary vaccination. A vaccine that is able to reduce acquisition of H. influenzae colonization in the nasopharynex can interrupt transmission, leading to protection of vulnerable populations through herd immunity.
Hib disease remains a major cause of childhood mortality in developing countries [25] , but the number of countries including Hib on their primary immunization schedule is rapidly expanding [26] . Long-term disease trends in the United States are encouraging for these countries, because there is no evidence of substantial replacement disease with non-b serotypes in young children. Nevertheless, in some countries, rates of Hib disease are similar to or greater than rates observed in American Indian and Alaska Native children [25] ; those countries might also continue to see a substantial burden of non-Hib disease. In addition, countries that implement a 3-dose primary series and no booster vaccine dose after age 12 months might not sustain low rates of Hib disease. Several years after implementing a 3-dose series, Hib disease rates increased in the United Kingdom, leading the country to move the third dose to after 12 months of age [27, 28] .
Since the introduction of Hib conjugate vaccines, the incidence of disease due to H. influenzae in the United States has decreased dramatically; however, there is still a substantial burden of non-Hib disease in the oldest and youngest age groups. Mortality associated with non-Hib disease in these age groups is similar to that seen with Hib disease. Studies are needed to identify risk factors for disease to determine how to maximize benefits from interventions designed to decrease incidence and severity in these age groups. In addition, although lower than in the pre-Hib vaccine era, American Indian and Alaska Native children aged ,5 years continue to be at significantly higher risk for invasive H. influenzae disease than other populations, and an early focus of interventions in this population should be a key consideration of H. influenzae disease prevention strategies in the United States.
Notes
